Trametinib

Spécifications

871700-17-3Numéro CAS

629-899-3Numéro CE

N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamideNom IUPAC

C26H23FIN5O4Formule chimique

615.4 g/molMasse molaire

Trametinib; 871700-17-3; GSK1120212; GSK-1120212; JTP 74057; GSK 1120212; JTP-74057; TMT212; trametinibum; TMT-212; N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; CHEBI:75998; 33E86K87QN; JTP74057; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide; Acetamide, N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]-; N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-1H,2H,3H,4H,6H,7H-pyrido[4,3-d]pyrimidin-1-yl}phenyl)acetamide; Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)-; N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-1H,2H,3H,4H,6H,7H-pyrido(4,3-d)pyrimidin-1-yl)phenyl)acetamide; N-(3-(3-CYCLOPROPYL-5-((2-FLUORO-4-IODOPHENYL)AMINO)-6,8-DIMETHYL-2,4,7-TRIOXO-3,4,6,7-TETRAHYDROPYRIDO(4,3-D)PYRIMIDIN-1(2H)-YL)PHENYL)ACETAMIDE; N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxopyrido(3,4-e)pyrimidin-1-yl)phenyl)acetamide; N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide; N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxopyrido[3,4-e]pyrimidin-1-yl]phenyl]acetamide; RefChem:57975; MEK Inhibitor GSK1120212; L01XE25; Mekinist; Trametinib (GSK1120212); N-[3-[3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetrahydro-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide; MFCD17215075; Trametinib [USAN]; N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; Trametinib (USAN); N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodo-anilino)-6,8-dimethyl-2,4,7-trioxo-pyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide; N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide; Trametinib [USAN:INN]; UNII-33E86K87QN; Trametinib?; N-(3-(3-Cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)acetamide; N-(3-{3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7- tetrahydropyrido(4,3-d)pyrimidin-1(2H)-yl}phenyl)acetamide; QOM; Trametinib (Standard); TRAMETINIB [MI]; Trametinib (GSK1120212JTP 74057); TRAMETINIB [INN]; TRAMETINIB [VANDF]; CPD 8B; TRAMETINIB [WHO-DD]; SCHEMBL170938; GTPL6495; orb1223790; orb1306425; GSK1120212 (Trametinib); CHEMBL2103875; SCHEMBL29355100; SCHEMBL29363416; EX-A022; LIRYPHYGHXZJBZ-UHFFFAOYSA-N; DTXSID901007381; GLXC-90070; HMS3295I05; HMS3656J11; HMS5081N13; BDBM50531540; EBC-17166; HY-10999R; NSC758246; NSC800956; s2673; AKOS015850628; CCG-264976; CS-0060; DB08911; EX-5957; FC34128; NSC-758246; NSC-800956; SB16553; SDCCGSBI-0646933.P001; NCGC00263180-01; NCGC00263180-05; NCGC00263180-07; NCGC00263180-14; AC-25891; AS-19382; BP-44059; HY-10999; SY067882; G7440; NS00040692; SW218089-2; T2125; D10175; EN300-25299821; GSK1120212,JTP-74057, GSK212; SR-01000941589; Q7833138; SR-01000941589-1; BRD-K12343256-001-01-4; BRD-K12343256-001-08-9; BRD-K12343256-001-11-3; BRD-K12343256-001-14-7; BRD-K12343256-001-18-8; Acetamide, N-(3-(3-cyclopropyl-5-((2-fluoro-4-iodophenyl)amino)-3,4,6,7-tetrahydro-6,8- dimethyl-2,4,7-trioxopyrido(4,3-d)pyrimidin-1(2H)-yl)phenyl)-; GSK-1120212TRAMETINIBMEKINISTA-1083G1357N-(3-{3-CYCLOPROPYL-5-[(2-FLUORO-4-IODOPHENYL)AMINO]-6,8-DIMETHYL-2,4,7-TRIOXO-3,4,6,7-TETRAHYDROPYRIDO[4,3-D]PYRIMIDIN-1(2H)-YL}PHENYL)ACETAMIDE GENERAL; N-(3-(3-Cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)pheny l)acetamide; N-(3-(3-cyclopropyl-5-(2-fluoro-4-iodophenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl)phenyl)acetamide; N-{3-[3-Cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl}ethanimidic acidSynonymes